NL294688A
(US20070167479A1-20070719-C00034.png)
|
1961-04-26 |
|
|
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US5001116A
(en)
|
1982-12-20 |
1991-03-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
US4994443A
(en)
|
1982-12-20 |
1991-02-19 |
The Children's Medical Center Corporation |
Inhibition of angiogenesis
|
US4551177A
(en)
|
1984-04-23 |
1985-11-05 |
National Starch And Chemical Corporation |
Compressible starches as binders for tablets or capsules
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US5391485A
(en)
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
JPS63500636A
(ja)
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするdna
|
US4810643A
(en)
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US5974203A
(en)
|
1988-04-11 |
1999-10-26 |
Canon Kabushiki Kaisha |
Pattern recognition communication apparatus for transmitting and receiving image data
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
CA2071479A1
(en)
|
1990-10-12 |
1992-04-13 |
Pamela Hunt |
Megakaryocyte maturation factors
|
US5387421A
(en)
|
1991-01-31 |
1995-02-07 |
Tsrl, Inc. |
Multi stage drug delivery system
|
WO1992014455A1
(en)
|
1991-02-14 |
1992-09-03 |
The Rockefeller University |
METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5358941A
(en)
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
US5360352A
(en)
|
1992-12-24 |
1994-11-01 |
The Whitaker Corporation |
Wire retainer for current mode coupler
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US20010056114A1
(en)
|
2000-11-01 |
2001-12-27 |
D'amato Robert |
Methods for the inhibition of angiogenesis with 3-amino thalidomide
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US6114355A
(en)
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
US5594637A
(en)
|
1993-05-26 |
1997-01-14 |
Base Ten Systems, Inc. |
System and method for assessing medical risk
|
US5698579A
(en)
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
US5641758A
(en)
|
1993-11-10 |
1997-06-24 |
Kluge; Michael |
Cytarabine derivatives, the preparation and use thereof
|
US6432924B1
(en)
|
1993-12-26 |
2002-08-13 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
GB9412394D0
(en)
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
BR9509357A
(pt)
|
1994-10-28 |
1997-12-30 |
Advanced Health Med E Systems |
Sistema de gerenciamento de prescrições implementado em computador prescrição combinação formada por uma instalação de computador central em um sistema de gerenciamento de prescrições embalagem dispositivo de indicação de dosagem e sistema de especifica o de produtos para o uso profissional
|
US5593696A
(en)
|
1994-11-21 |
1997-01-14 |
Mcneil-Ppc, Inc. |
Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
|
US5619991A
(en)
|
1995-04-26 |
1997-04-15 |
Lucent Technologies Inc. |
Delivery of medical services using electronic data communications
|
US5643915A
(en)
|
1995-06-06 |
1997-07-01 |
Andrulis Pharmaceuticals Corp. |
Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
|
US5731325A
(en)
|
1995-06-06 |
1998-03-24 |
Andrulis Pharmaceuticals Corp. |
Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
|
US5832449A
(en)
|
1995-11-13 |
1998-11-03 |
Cunningham; David W. |
Method and system for dispensing, tracking and managing pharmaceutical trial products
|
US6063026A
(en)
|
1995-12-07 |
2000-05-16 |
Carbon Based Corporation |
Medical diagnostic analysis system
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
DE69717831T3
(de)
|
1996-07-24 |
2018-08-30 |
Celgene Corp. |
Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
DE69720735T9
(de)
|
1996-08-12 |
2005-08-25 |
Celgene Corp. |
Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
|
US5924074A
(en)
|
1996-09-27 |
1999-07-13 |
Azron Incorporated |
Electronic medical records system
|
ATE305301T1
(de)
|
1996-11-05 |
2005-10-15 |
Childrens Medical Center |
Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
|
US6131090A
(en)
|
1997-03-04 |
2000-10-10 |
Pitney Bowes Inc. |
Method and system for providing controlled access to information stored on a portable recording medium
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
AU729529B2
(en)
|
1997-06-06 |
2001-02-01 |
Depomed, Inc. |
Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
|
AU8909898A
(en)
|
1997-08-22 |
1999-03-16 |
Deka Products Limited Partnership |
Health care system and method for physician order entry
|
US5874448A
(en)
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
US5955476A
(en)
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
US6096757A
(en)
|
1998-12-21 |
2000-08-01 |
Schering Corporation |
Method for treating proliferative diseases
|
CN100390163C
(zh)
|
1998-03-16 |
2008-05-28 |
赛尔金有限公司 |
2-(2,6-二氧哌啶-3-基)-异二氢吲哚衍生物、其制法及其作为炎性细胞因子抑制剂的用途
|
JPH11286455A
(ja)
|
1998-03-31 |
1999-10-19 |
Kanebo Ltd |
骨髄異形成症候群治療薬
|
US6673828B1
(en)
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
US6020358A
(en)
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
US20030013739A1
(en)
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
GB9904585D0
(en)
|
1999-02-26 |
1999-04-21 |
Gemini Research Limited |
Clinical and diagnostic database
|
ES2250121T3
(es)
|
1999-03-18 |
2006-04-16 |
Celgene Corporation |
1-oxo- y 1,3-dioxoisoindolinas y su empleo en composiciones farmaceuticas para la reduccion de niveles de las citocinas inflamatorias.
|
US20010021380A1
(en)
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
CA2379313A1
(en)
|
1999-07-16 |
2001-01-25 |
Amato Pharmaceutical Products, Ltd. |
Glycyrrhizin preparations for transmucosal absorption
|
US6202923B1
(en)
|
1999-08-23 |
2001-03-20 |
Innovation Associates, Inc. |
Automated pharmacy
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
CA2319872C
(en)
|
2000-02-02 |
2012-06-19 |
Chun-Ying Huang |
Pharmaceutical composition for the treatment of hepatocellular carcinoma
|
WO2001056544A2
(en)
|
2000-02-04 |
2001-08-09 |
Depomed, Inc. |
Shell-and-core dosage form approaching zero-order drug release
|
TR200202194T2
(tr)
|
2000-03-17 |
2003-01-21 |
Cell Therapeutics, Inc. |
Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
|
MXPA02009665A
(es)
|
2000-03-31 |
2005-09-08 |
Celgene Corp |
Inhibicion de actividad de ciclooxigenasa-2.
|
ATE322265T1
(de)
|
2000-05-15 |
2006-04-15 |
Celgene Corp |
Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
|
JP5409981B2
(ja)
|
2000-05-15 |
2014-02-05 |
セルジーン コーポレイション |
癌治療用の組成物および方法
|
AU2001280161A1
(en)
|
2000-08-24 |
2002-03-04 |
Kirin Beer Kabushiki Kaisha |
C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
ATE374609T1
(de)
|
2000-11-30 |
2007-10-15 |
Childrens Medical Center |
Synthese von 4-aminothalidomid enantiomeren
|
US20020128228A1
(en)
|
2000-12-01 |
2002-09-12 |
Wen-Jen Hwu |
Compositions and methods for the treatment of cancer
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
GB0102342D0
(en)
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
WO2002068414A2
(en)
|
2001-02-27 |
2002-09-06 |
The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
JP4494013B2
(ja)
|
2001-08-06 |
2010-06-30 |
ザ チルドレンズ メディカル センター コーポレイション |
窒素置換サリドマイド誘導体の合成及び抗腫瘍活性
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
JP4027693B2
(ja)
|
2002-03-20 |
2007-12-26 |
トリニティ工業株式会社 |
塗料送給装置及びバルブユニット
|
US20030220254A1
(en)
|
2002-03-29 |
2003-11-27 |
Texas Tech University System |
Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
JP2005536189A
(ja)
|
2002-04-12 |
2005-12-02 |
セルジーン・コーポレーション |
血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
CN1697655B
(zh)
|
2002-05-17 |
2013-09-18 |
细胞基因公司 |
使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物
|
NZ536908A
(en)
|
2002-05-17 |
2008-09-26 |
Celgene Corp |
Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
WO2004041195A2
(en)
|
2002-10-31 |
2004-05-21 |
Supergen, Inc. |
Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
|
US20040091455A1
(en)
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US20040152632A1
(en)
|
2002-11-06 |
2004-08-05 |
Wyeth |
Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
|
US6943249B2
(en)
|
2003-03-17 |
2005-09-13 |
Ash Stevens, Inc. |
Methods for isolating crystalline Form I of 5-azacytidine
|
US6887855B2
(en)
|
2003-03-17 |
2005-05-03 |
Pharmion Corporation |
Forms of 5-azacytidine
|
CL2004001004A1
(es)
|
2003-05-19 |
2005-03-18 |
Upjohn Co |
Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
JP2007532642A
(ja)
|
2004-04-14 |
2007-11-15 |
セルジーン・コーポレーション |
脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
|
BRPI0418742A
(pt)
|
2004-04-14 |
2007-09-11 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
US20060128654A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
US20070155791A1
(en)
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
US8058260B2
(en)
|
2006-05-22 |
2011-11-15 |
Xenoport, Inc. |
2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
|
AU2007281684C1
(en)
*
|
2006-08-07 |
2013-12-19 |
Abbvie Biotherapeutics Inc. |
Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
WO2008027049A1
(en)
|
2006-08-30 |
2008-03-06 |
Temple University - Of The Commonwealth System Of Higher Education |
Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
|
US20080057086A1
(en)
|
2006-09-01 |
2008-03-06 |
Pharmion Corporation |
Colon-targeted oral formulations of cytidine analogs
|
PL2420498T3
(pl)
|
2006-09-26 |
2017-10-31 |
Celgene Corp |
5-podstawione pochodne chinazolinonu jako środki przeciwnowotworowe
|
CN101952272B
(zh)
|
2007-09-26 |
2014-08-27 |
细胞基因公司 |
6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain vehicles, installations and methods
|
US20100311683A1
(en)
|
2007-11-01 |
2010-12-09 |
Beach C L |
Cytidine analogs for treatment of myelodysplastic syndromes
|
PT3782612T
(pt)
|
2008-05-15 |
2024-01-18 |
Celgene Corp |
Formulações orais de análogos da citidina e métodos de utilização dos mesmos
|
SI2358697T1
(sl)
|
2008-10-29 |
2016-02-29 |
Celgene Corporation |
Spojine izoindolina za uporabo pri zdravljenju raka
|
US8628927B2
(en)
|
2008-11-07 |
2014-01-14 |
Sequenta, Inc. |
Monitoring health and disease status using clonotype profiles
|
ES2728776T3
(es)
|
2009-05-19 |
2019-10-28 |
Celgene Corp |
Formulaciones de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona
|
EP4289838A3
(en)
|
2010-02-11 |
2024-03-13 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
HUE027481T2
(en)
|
2011-03-11 |
2016-09-28 |
Celgene Corp |
Methods of treating cancer with 3- (5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl) -piperidine-2,6-dione
|
US20140142128A1
(en)
|
2012-11-20 |
2014-05-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
CN107249604A
(zh)
*
|
2014-12-31 |
2017-10-13 |
人类起源公司 |
使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|
SI3313528T1
(sl)
*
|
2015-06-29 |
2021-11-30 |
Bristol-Myers Squibb Company |
Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka
|